DHR — Q1 2026 Earnings Preview
Danaher Corporation | Reports April 21, 2026 Before Market Open | Life Sciences Tools & Medical Diagnostics | ~$138B market cap | Preview date: April 14, 2026
Earnings Date
Apr 21
2026 BMO — 7 days away
Q1 EPS Consensus
$1.94
vs. $1.88 actual Q1 2025 (+3.2% YoY)
FY2026 EPS Guide
$8.35–$8.50
Mid $8.43 · +8.1% vs. FY2025 $7.80
5-Quarter Beat Rate
100%
Q4 2024 – Q4 2025 · Avg beat +7.9%
Stock vs 52-Wk High
-19.3%
$195.87 vs. $242.80 high · $180 low
Avg Analyst PT
~$246
+25.6% implied · 3 cuts in April alone
Tariff Headwind
$350M
Gross COGS impact — NOT in Jan 28 guide
Masimo Deal
$9.9B
$180/share cash · H2 2026 close expected
Investment Setup: Three Questions Define the Quarter
1. Bioprocessing equipment orders: Management has spent 5 consecutive quarters arguing equipment is "in early innings of recovery." The street doesn't believe it — Goldman, Evercore, and Jefferies all cut PTs in the 8 days before this print. If Q1 2026 shows even low-single-digit equipment order inflection, the management-street divergence thesis resolves in DHR's favor.
2. Tariff guidance maintenance: ~$350M gross tariff headwind was NOT in the Jan 28 FY2026 EPS guide ($8.35–$8.50). Management claims manufacturing offsets. Can they maintain EPS guidance while absorbing this? At 22.6x forward P/E, a guidance cut would be a painful multiple compression event.
3. Life Sciences floor: OP margins collapsed from 20.2% (FY2022) to 12.0% (FY2025). NIH funding uncertainty and Aldevron are the culprits. Any trough signal here — even "stable at 12%" — would be constructive for the recovery narrative.
Guidance from Q4 2025 earnings call (January 28, 2026). DHR does not provide quarterly EPS guidance — only directional metrics.
| Metric | Guidance | Street Consensus | Notes |
|---|---|---|---|
| Core Revenue Growth | Up low single digits | ~+2%–3% | Acceleration from Q4 2025 (+2.5%); FX headwind modest |
| Total Revenue (est.) | ~$5.86B implied | ~$5.9B | vs. $5.73B in Q1 2025; +2.3% total growth |
| Adj. Operating Profit Margin | ~28.5% | ~28–28.5% | Flat YoY vs. Q1 2025 (~29.6%); cost actions partially offset |
| Adj. Diluted EPS (implied) | Not guided explicitly | $1.94 | vs. $1.88 Q1 2025 (+3.2% YoY); 5 consecutive beats avg +7.9% |
| Cepheid Respiratory Revenue | ~$500M | ~$500M | Full-year ~$1.8B; COVID normalization; Q1 seasonal respiratory peak |
| Bioprocessing | High-single-digit growth | ~+7%–9% | Consumables leading; equipment flat — but watch for inflection |
Context: DHR's 5-quarter EPS beat average of +7.9% is unusually large — Q1 2025's +14.4% beat inflated the average. A more conservative estimate of the structural beat margin is ~4–5%, which would imply ~$2.02–2.03 for Q1 2026. Note that Q1 2025 ($1.88 actual) already embedded a large respiratory outperformance vs. expectations at the time. The ~$500M respiratory guide for Q1 2026 is explicit — less upside surprise available from that component.
Critical note: FY2026 guidance was issued January 28, 2026. The April 2026 reciprocal tariffs (~$350M gross impact) were NOT reflected. Management has indicated they expect to 'largely offset' via manufacturing footprint changes.
| Metric | Guide Low | Guide High | Midpoint | Consensus (Apr 2026) |
|---|---|---|---|---|
| Core Revenue Growth | +3% | +6% | +4.5% | ~+4–5% |
| Total Revenue (est.) | ~$25.4B | ~$26.1B | ~$25.7B | ~$25.9B |
| Adj. Diluted EPS | $8.35 | $8.50 | $8.43 | $8.40 |
| Adj. Operating Margin | — | — | >100bps expansion | ~29.4–30.0% |
| Cepheid Respiratory | — | — | ~$1.8B | ~$1.8B |
| Cost Actions Benefit | — | — | ~$0.30/share EPS | ~$250M net savings |
Tariff overhang on guidance: April 2026 reciprocal tariffs add ~$350M gross to COGS — approximately $0.25/share pre-offset. If manufacturing footprint changes and pricing recover only 50% of this, the net EPS headwind is ~$0.12/share, which would push FY2026 EPS to ~$8.18–$8.33 at the midpoint — below the guided range. Management guidance maintenance on April 21 requires credible offset narrative.
| Segment | FY2025 Rev | FY2026 Direction | FY2025 OP Margin | Key Watch |
|---|---|---|---|---|
| Biotechnology | $7.3B | High single-digit growth | 24.9% | Equipment inflection from flat? Consumables +HSD confirmed. Equipment cycle thesis test. |
| Life Sciences | $7.3B | Low single-digit growth | 12.0% | NIH/academic funding drag; IDT (Aldevron) normalization; OP margin trough watch. |
| Diagnostics | $9.9B | Low single-digit growth | 26.8% | Cepheid ~$1.8B resp.; non-resp. +20%+; China VBP ~$150M headwind; menu expansion. |
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue ($M) | $5,792 | $5,738 | $5,869 | $6,497 | $5,730 | $5,930 | $6,135 | $6,800 |
| YoY Rev Growth | -25.0% | -19.9% | -14.6% | +9.1% | -1.1% | +3.3% | +4.5% | +4.7% |
| Core Rev Growth | (7.5)% | (3.5)% | (1.0)% | +1.0% | flat | +1.5% | +3.0% | +2.5% |
| Biotechnology ($M) | ~$2,800 | ~$2,800 | ~$2,950 | ~$3,300 | ~$3,010 | ~$3,000 | ~$3,100 | ~$3,520 |
| Life Sciences ($M) | ~$1,280 | ~$1,250 | ~$1,260 | ~$1,290 | ~$1,230 | ~$1,220 | ~$1,250 | ~$1,300 |
| Diagnostics ($M) | ~$1,712 | ~$1,688 | ~$1,659 | ~$1,907 | ~$1,490 | ~$1,710 | ~$1,785 | ~$1,980 |
| Adj. Diluted EPS | $1.92 | $1.72 | $1.71 | $2.14 | $1.88 | $1.80 | $1.89 | $2.23 |
| EPS YoY Growth | -18.6% | -16.1% | -15.3% | +2.4% | -2.1% | +4.7% | +10.5% | +4.2% |
| Free Cash Flow ($M) | $1,448 | $1,131 | $1,226 | $1,504 | $1,060 | $1,094 | $1,370 | $1,769 |
| FCF YoY Growth | -13.4% | -28.8% | -6.5% | +29.3% | -26.8% | -3.3% | +11.7% | +17.6% |
Trajectory: Core revenue growth has moved from trough (7.5)% in Q1 2024 to +3.0% in Q3 2025 and +2.5% in Q4 2025 — a genuine 8-quarter recovery. EPS troughed at $1.71 in Q3 2024 and has grown every quarter since ($1.71 to $2.23 = +30% in 3 quarters). FCF recovery is particularly strong: Q4 2025 FCF of $1,769M +17.6% YoY, FY2025 FCF = $5.3B for the 34th consecutive year of >100% FCF/NI conversion. The Q4 2025 adj. OP margin of 28.3% (-140 bps YoY) is a concern — productivity investments taken in-period. Management guides ~28.5% for Q1 2026 and >100bps full-year expansion.
Daloopa series 6076342 (total company adj. OP margin, Non-GAAP). Q1 2024 not available in this series; implied ~29.9% based on FY2024 average.
| Metric | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % (GAAP) | 60.2% | 59.7% | 58.7% | 59.5% | 61.2% | 59.3% | 58.2% | 58.0% |
| YoY bps change | -80 bps | +320 bps | +50 bps | +50 bps | +100 bps | -40 bps | -50 bps | -150 bps |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|---|---|
| Adj. OP Margin % (Non-GAAP) | 27.3% | 27.5% | 29.7% | 29.6% | 27.3% | 27.9% | 28.3% |
| YoY bps change | n/a | n/a | n/a | n/a | 0 bps | +40 bps | -140 bps |
Q4 2025 adj. OP margin of 28.3% was -140 bps YoY and -130 bps vs. Q3 2025 — driven by in-period productivity investments not adjusted out and China VBP impact in Diagnostics. Management guided Q1 2026 at ~28.5% (flat to slight expansion from Q4 2025). The >100 bps full-year expansion guide assumes cost actions flowing through in H2 2026 and volume leverage from bioprocessing. FY2026 adj. OP margin of ~29.4–30.0% would be a 5-year high — achievable if the bioprocessing equipment cycle turns.
DHR does not provide quarterly EPS guidance. Beat/miss measured vs. sell-side consensus estimate. 5 consecutive beats through Q4 2025.
| Quarter | Consensus | Actual EPS | Delta $ | Delta % | Result |
|---|---|---|---|---|---|
| Q4 2024 | $2.09 | $2.14 | +$0.05 | +2.4% | BEAT |
| Q1 2025 | $1.62 | $1.88 | +$0.26 | +14.4% | BEAT |
| Q2 2025 | $1.64 | $1.80 | +$0.16 | +9.5% | BEAT |
| Q3 2025 | $1.72 | $1.89 | +$0.17 | +10.5% | BEAT |
| Q4 2025 | $2.17 | $2.23 | +$0.06 | +2.8% | BEAT |
| Q1 2026 (Preview) | $1.94 | TBD Apr 21 | — | — | — |
Q1 2025's +14.4% beat (+$0.26 vs. consensus) is the outlier — driven primarily by Cepheid respiratory significantly outperforming the low initial expectations set at guidance time. With respiratory now explicitly guided at ~$500M for Q1 2026 (vs. being a surprise upside in Q1 2025), the variance is more predictable. The structural 4-5% beat pattern is more reliable. Applied to $1.94 consensus: structural beat implies $2.02–$2.04 range. A +14% outlier beat is unlikely without another Cepheid surprise.
Management initiated FY2025 EPS guidance at $7.60–$7.75 at Q1 2025 call and delivered $7.80 at the top end. Apply conservatism discount to the FY2026 guide ($8.35–$8.50).
| Guided At | FY2025 EPS Range | Context |
|---|---|---|
| Q4 2024 call (Jan 29, 2025) | No EPS guide issued | Core rev +3%; adj. OP margin ~28.5% |
| Q1 2025 call (Apr 22, 2025) | $7.60 – $7.75 | First EPS guidance; above early consensus |
| Q2 2025 call (Jul 22, 2025) | $7.70 – $7.80 | Raised on strong bioprocessing consumables |
| Q3 2025 call (Oct 21, 2025) | $7.70 – $7.80 | Maintained at top of range; narrowed |
| FY2025 Actual | $7.80 | Delivered at top end — 5th consecutive EPS beat |
FY2026 conservatism signal: FY2025 EPS was delivered at the top end of the final range (=$7.80 vs. $7.70–$7.80). If the FY2026 beat-and-raise pattern holds: initial guide $8.35–$8.50 → final delivery could approach $8.75–$8.90 before accounting for tariff headwinds (~$0.10–$0.15/share net impact after offsets). The risk is that tariffs represent an unusual mid-year external shock that disrupts the normal raise cadence. Q1 2026 commentary on tariff offset timeline is the key input.
| Date | Headline | Detail | Significance |
|---|---|---|---|
| Feb 17, 2026 | Masimo Acquisition Announced | $9.9B cash deal at $180/share for Masimo Corp (patient monitoring + consumer wearables, ~$2B revenue). Expected H2 2026 close pending regulatory review. | Largest acquisition since Cytiva; DBS playbook applicable but Aldevron write-downs create credibility overhang on M&A execution |
| Feb 28, 2026 | CFO Transition: Gugino Succeeds McGrew | Matt Gugino officially becomes CFO. 12-year DHR veteran (former VP IR, Group CFO Life Sciences). Matt McGrew moves to advisory EVP role before retirement. | Orderly internal succession; lower risk than external hire; continuity in financial communication expected |
| Apr 2026 | Reciprocal Tariff Headwind Emerges | U.S. imposes sweeping reciprocal tariffs. DHR estimates ~$350M gross cost impact. NOT included in Jan 28, 2026 FY2026 guidance ($8.35–$8.50 EPS). Management expects to largely offset via manufacturing footprint. | Most critical new variable for Q1 2026 call — maintenance of EPS guidance depends on offset credibility |
| Apr 6, 2026 | Evercore ISI PT Cut: $254 to $225 | Maintained Outperform. Added to Tactical Outperform list. Cut reflects near-term macro uncertainty, not thesis change. | Second large broker PT cut into Q1 2026 earnings; pattern of sell-side caution vs. management bullishness |
| Apr 10, 2026 | Jefferies PT Lowered | PT reduced. Macro/tariff uncertainty cited. No new company-specific thesis. | Continuation of sell-side PT cut pattern ahead of Q1 print |
| Apr 13, 2026 | Goldman Sachs PT Cut: $265 to $230 | Maintained Buy rating. Cited macro headwinds and tariff uncertainty. PT cut of $35 is the largest single adjustment in recent history. | Three major broker cuts in eight days before April 21 earnings — management-street divergence at maximum before Q1 results |
Consensus: ~13 Buy / 2 Hold / 0 Sell (StockAnalysis). Average PT ~$246 (~+25.6% implied upside from $195.87). Three major PT cuts in April 2026 before Q1 print.
| Firm | Action | Price Target | Date |
|---|---|---|---|
| Goldman Sachs | PT cut; Buy maintained | $265 → $230 | Apr 13, 2026 |
| Evercore ISI | PT cut; Outperform + Tactical OP | $254 → $225 | Apr 6, 2026 |
| Jefferies | PT lowered | n/a | Apr 10, 2026 |
| Rothschild Redburn | Downgrade: Buy to Neutral | $220 | Recent |
Management-street divergence at maximum tension: Three major brokers cut PTs in the 8 days before Q1 2026 earnings, while management has held its FY2026 $8.35–$8.50 guidance and consistently communicated bioprocessing recovery confidence. The PT cuts reflect tariff uncertainty and macro caution — not a thesis change on bioprocessing. This is the exact setup the dim_4 investor sentiment analysis flagged: sell-side growing cautious while management holds firm. Q1 2026 will either validate or break the management-street divergence thesis.
Equipment Order Inflection
Management's core thesis: brownfield expansions, pharma reshoring, and biosimilar volume are thawing capital budgets. Even +5% equipment growth vs. flat guidance adds ~$0.03/share directly and ~$0.10/share via consumable lead-time in H2 2026. 5 consecutive quarters of bioprocessing order growth provides the foundation.
Life Sciences Recovery (Underpriced)
LS OP margin at 12.0% vs. 20.2% at peak. A recovery to 15–16% FY2026 (Scenario A in dim_5 analysis) adds ~$350–450M operating income — roughly $0.25/share EPS. Street is NOT modeling this recovery; it's the most underanalyzed positive surprise scenario.
$250M Cost Actions (FY2026)
Management guided ~$0.30/share EPS tailwind from $250M net savings. These are largely structural (headcount rationalization, facility consolidation) — not volume dependent. This is a reliable building block for FY2026 EPS regardless of macro.
Cytiva Moat — Regulatory Lock-In
~80% share in protein A chromatography resin for 20–30 years. Switching requires 2–5 year FDA re-validation of approved biologics CMC filings. Over 90% of global mAb production runs Cytiva-supported platforms. This moat is structurally immune to near-term macro.
Cepheid Non-Respiratory Expansion
Non-respiratory growing >20% consistently. Expert GI Panel FDA cleared Jan 2026 kicks off menu expansion. 40,000+ GeneXpert installed base in 180+ countries = captive recurring reagent revenue at high margins. Non-resp is the long-term underappreciated compounder within Diagnostics.
Tariff Offset Not Credible
~$350M gross tariff headwind = ~$0.25/share pre-offset. Manufacturing footprint changes take 12–24 months to fully execute. If only 50% of the gross impact is offset, FY2026 EPS falls ~$0.12/share below the guidance midpoint. At 22.6x forward P/E, a guidance cut would trigger meaningful multiple compression.
Masimo Execution Risk
$9.9B acquisition follows Aldevron ($9.6B deal with $500M+ impairments). Masimo consumer wearables are outside DHR's core lab/industrial competency. If DBS playbook is poorly applied or Masimo underperforms the deal model, M&A credibility erodes further. Aldevron was the cautionary case; investors are watching capital allocation carefully.
Life Sciences Stays Depressed
Scenario B (30-35% probability in dim_5): NIH/academic funding suppressed for 2+ years keeps LS growth flat and margins at 12–13%. IDT/Aldevron continues to underperform. This is the most underanalyzed risk — not in consensus models and difficult to detect until multiple missed quarters confirm the trough is not in.
China VBP + Tariff Compounding
China (~11% revenue, ~$2.7B) faces layered headwinds: $150M VBP headwind in Diagnostics AND new tariff exposure AND localization mandates. If China deteriorates beyond current guidance, a segment-level write-down or guidance revision is possible. 2025 had $150M headwind — 2026 could be larger.
No Insider Buying at Discount
Stock trades 19% below 52-week high. No open-market purchases by CEO Rainer Blair or CFO Gugino. The Rales family sold ~$483M over the past year. Management is verbally bullish on recovery but no one is putting personal capital behind the thesis at $195. This limits the conviction signal.
1. Equipment Orders: The Core Inflection Signal
Management has guided bioprocessing equipment 'flat' for FY2026 but has spent 5 consecutive quarters citing brownfield expansions, pharma reshoring, and biosimilar volume. If Q1 2026 shows ANY equipment order inflection from flat to even low-single-digit positive, the bull case for FY2026-2027 activates materially. Equipment leads consumables by 2-3 quarters — a +5% equipment quarter implies ~$0.10/share of additional consumable revenue in H2 2026. Goldman and Evercore cut PTs just days before this call without embedding this scenario. This is where the management-street divergence resolves or doesn't.
2. Tariff Impact: EPS Guide Maintenance or Cut?
The Jan 28, 2026 FY2026 guidance ($8.35-$8.50 EPS) did NOT include the April 2026 reciprocal tariffs. DHR estimates ~$350M gross COGS impact. Management expects 'largely offset' via manufacturing footprint changes and pricing. The critical question: will FY2026 EPS guidance be maintained, narrowed, or cut? Maintaining guidance absorbs the tariff and signals strong business execution. Any cut would be a negative catalyst at 22.6x forward P/E.
3. Life Sciences Operating Margin: Is 12% the Trough?
Life Sciences operating margin collapsed from 20.2% (FY2022) to 12.0% (FY2025) — a 820 bps decline. NIH/academic funding uncertainty and Aldevron underperformance drove the collapse. Q1 2026 commentary on Life Sciences trajectory (particularly IDT normalization and academic demand) will signal whether FY2026 margin recovery (management scenario: 15-16% at midpoint) is on track. This segment alone has ~$500-700M of operating income recovery potential vs. FY2022 levels.
4. Cepheid Non-Respiratory Momentum
Respiratory revenue of ~$500M is expected for Q1 2026 (~$1.8B FY2026). The higher-quality metric is non-respiratory growing >20% consistently. Watch for Expert GI Panel FDA clearance (Jan 2026) uptake, HIV/TB/STI menu expansion, and GeneXpert installed base additions. Non-respiratory is the long-duration value driver — management bullishness here is most credible.
5. Masimo Integration Timeline and Rationale
The $9.9B Masimo acquisition was announced Feb 17, 2026. At ~$180/share cash, this is DHR's largest deal since Cytiva. Q1 2026 call should provide: (1) regulatory approval status, (2) expected synergy cadence, (3) whether the DBS playbook is being prepared for deployment. Masimo adds patient monitoring and consumer wearables — a pivot from DHR's pure life-science tools identity. Aldevron ($9.6B, >$500M impairments) is the cautionary precedent; management must demonstrate capital discipline.
6. China VBP: Headwind Quantification and Tariff Layering
China represents ~11% of DHR revenue (~$2.7B). Volume-based purchasing (VBP) has driven ~$150M annual headwind in Diagnostics. With new tariffs now layered on top, the combined China risk may exceed $350-400M annually. Watch for any management update to China headwind guidance and whether localization investments are accelerating. A worsening China outlook would stress the FY2026 guidance significantly.
7. FY2026 Core Revenue Guidance: 3-6% Intact?
FY2026 guided at 3-6% core revenue growth. With tariff uncertainty and potential Life Sciences softness, the low end (3%) is most at risk. Specifically: bioprocessing consumables (high-single-digit guide) is the key driver. If the equipment cycle and consumables continue, 4-5% core growth is achievable. Watch for any language suggesting the 3-6% range needs to be revisited.
| Date | Ticker | Company | Period | Read-Across |
|---|---|---|---|---|
| Apr 21, 2026 BMO | DHR | Danaher | Q1 2026 | This Report |
| Apr 23, 2026 BMO | TMO | Thermo Fisher Scientific | Q1 2026 | Largest peer; bioprocessing/LS read-across |
| Apr 30, 2026 | WAT | Waters Corp | Q1 2026 | Instruments/analytical chemistry; LS tools |
| May 6, 2026 | IDXX | IDEXX Laboratories | Q1 2026 | Veterinary diagnostics; different end market |
| May 8, 2026 | MTD | Mettler-Toledo | Q1 2026 | Instruments/precision tools; LS exposure |
TMO read-across (Apr 23 — 2 days after DHR): Thermo Fisher is the most important peer report. TMO's bioprocessing commentary on Life Sciences revenue, pharma customer capex, and any guidance change will either confirm or challenge DHR's FY2026 recovery narrative. If TMO shows accelerating bioprocessing orders, DHR's equipment inflection thesis gets immediate validation. If TMO is cautious, expect DHR multiple pressure.